MAP3K7CL anticorps (C-Term)
Aperçu rapide pour MAP3K7CL anticorps (C-Term) (ABIN629829)
Antigène
Voir toutes MAP3K7CL AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- C-Term
-
Specificité
- C21 ORF7 antibody was raised against the C terminal Of C21 rf7
-
Purification
- Purified
-
Immunogène
- C21 ORF7 antibody was raised using the C terminal Of C21 rf7 corresponding to a region with amino acids DSEESMEVFKQHCQIAEEYHEVKKEITLLEQRKKELIAKLDQAEKEKVDA
-
-
-
-
Indications d'application
-
WB: 1.25 µg/mL, IHC: 4-8 µg/mL
Optimal conditions should be determined by the investigator. -
Commentaires
-
C21ORF7 Blocking Peptide, (ABIN937547), is also available for use as a blocking control in assays to test for specificity of this C21ORF7 antibody
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Lyophilized powder. Add distilled water for a 1 mg/mL concentration of C20 RF7 antibody in PBS
-
Concentration
- Lot specific
-
Buffer
- PBS
-
Conseil sur la manipulation
-
Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use. -
Stock
- 4 °C/-20 °C
-
Stockage commentaire
- Store at 2-8 °C for short periods. For longer periods of storage, store at -20 °C.
-
-
- MAP3K7CL (MAP3K7 C-Terminal Like (MAP3K7CL))
-
Autre désignation
- C21ORF7
-
Sujet
- C21orf7 plays a critical role in the TGF-beta signaling transduction pathway.
-
Poids moléculaire
- 27 kDa (MW of target protein)
Antigène
-